CN109154611B - 人源化抗cd73抗体 - Google Patents

人源化抗cd73抗体 Download PDF

Info

Publication number
CN109154611B
CN109154611B CN201680081339.6A CN201680081339A CN109154611B CN 109154611 B CN109154611 B CN 109154611B CN 201680081339 A CN201680081339 A CN 201680081339A CN 109154611 B CN109154611 B CN 109154611B
Authority
CN
China
Prior art keywords
position corresponding
kabat
kabat position
antibody
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680081339.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN109154611A (zh
Inventor
E·P·格里芬
R·A·米勒
G·J·弗雷
H·W·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Corvus Pharmaceuticals Inc
Original Assignee
Bioatla Inc
Corvus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioatla Inc, Corvus Pharmaceuticals Inc filed Critical Bioatla Inc
Priority to CN202210276366.6A priority Critical patent/CN114805575B/zh
Publication of CN109154611A publication Critical patent/CN109154611A/zh
Application granted granted Critical
Publication of CN109154611B publication Critical patent/CN109154611B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680081339.6A 2015-12-09 2016-12-09 人源化抗cd73抗体 Active CN109154611B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210276366.6A CN114805575B (zh) 2015-12-09 2016-12-09 人源化抗cd73抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562265357P 2015-12-09 2015-12-09
US62/265,357 2015-12-09
US201662289694P 2016-02-01 2016-02-01
US62/289,694 2016-02-01
US201662346327P 2016-06-06 2016-06-06
US62/346,327 2016-06-06
PCT/US2016/065968 WO2017100670A1 (en) 2015-12-09 2016-12-09 Humanized anti-cd73 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210276366.6A Division CN114805575B (zh) 2015-12-09 2016-12-09 人源化抗cd73抗体

Publications (2)

Publication Number Publication Date
CN109154611A CN109154611A (zh) 2019-01-04
CN109154611B true CN109154611B (zh) 2022-04-08

Family

ID=59013359

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210276366.6A Active CN114805575B (zh) 2015-12-09 2016-12-09 人源化抗cd73抗体
CN201680081339.6A Active CN109154611B (zh) 2015-12-09 2016-12-09 人源化抗cd73抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210276366.6A Active CN114805575B (zh) 2015-12-09 2016-12-09 人源化抗cd73抗体

Country Status (13)

Country Link
US (2) US10822426B2 (ko)
EP (1) EP3387442A4 (ko)
JP (2) JP7391510B2 (ko)
KR (1) KR20180134837A (ko)
CN (2) CN114805575B (ko)
AU (1) AU2016366548C1 (ko)
CA (1) CA3007646A1 (ko)
CL (1) CL2018001512A1 (ko)
EA (1) EA201891366A1 (ko)
IL (1) IL259927B2 (ko)
MX (1) MX2018006973A (ko)
WO (1) WO2017100670A1 (ko)
ZA (1) ZA201803874B (ko)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201891366A1 (ru) 2015-12-09 2018-12-28 Корвус Фармасьютикалз, Инк. Гуманизированные антитела против cd73
WO2018013611A1 (en) * 2016-07-11 2018-01-18 Corvus Pharmaceuticals, Inc. Anti-cd73 antibodies
ES2908662T3 (es) 2017-01-24 2022-05-03 I Mab Biopharma Us Ltd Anticuerpos anti-CD73 y usos de los mismos
WO2018167267A1 (en) 2017-03-16 2018-09-20 Innate Pharma Compositions and methods for treating cancer
WO2018187512A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
CA3074588A1 (en) 2017-10-06 2019-04-11 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
CN112384515A (zh) 2018-02-27 2021-02-19 因赛特公司 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶
CN110240654A (zh) 2018-03-07 2019-09-17 复旦大学 结合cd73的抗体-药物偶联物
CA3093468A1 (en) * 2018-03-09 2019-09-12 Agenus Inc. Anti-cd73 antibodies and methods of use thereof
AU2019231172B2 (en) 2018-03-09 2023-08-24 Phanes Therapeutics, Inc. Anti-CD73 antibodies and uses thereof
US20210024873A1 (en) 2018-03-27 2021-01-28 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
BR112020024412A8 (pt) 2018-06-18 2023-03-21 Innate Pharma Anticorpos, composição farmacêutica, kit, ácido nucleico, célula hospedeira, métodos de tratamento ou prevenção de câncer, de redução da atividade, de aumento da atividade e de aumento da ativação
EP3818063A1 (en) 2018-07-05 2021-05-12 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
WO2020097127A2 (en) * 2018-11-05 2020-05-14 Corvus Pharmaceuticals, Inc. B-cell activating cd73 antibodies
US20220220218A1 (en) * 2018-11-12 2022-07-14 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
CN111434688A (zh) * 2019-01-11 2020-07-21 上海开拓者生物医药有限公司 Cd73抗体及其制备方法和应用
CN111499747B (zh) * 2019-01-11 2022-03-18 康诺亚生物医药科技（成都）有限公司 一种抗cd73单克隆抗体及其应用
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
CA3136698A1 (en) 2019-04-23 2020-10-29 Innate Pharma Cd73 blocking antibodies
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
MX2021014952A (es) * 2019-06-06 2022-04-06 Jacobio Pharmaceuticals Co Ltd Molecula de union especifica para cd73 y uso de la molecula de union.
CN112300279A (zh) * 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
WO2021032173A1 (en) * 2019-08-21 2021-02-25 Harbour Biomed (Shanghai) Co., Ltd. Anti-cd73 antibody and application thereof
US11634500B2 (en) 2019-09-06 2023-04-25 Les Laboratoires Servier Anti-CD73 antibodies and compositions
AU2020373124A1 (en) * 2019-11-01 2022-05-19 Corvus Pharmaceuticals, Inc. Immunomodulatory anti-CD73 antibodies and uses thereof
WO2021138498A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
CN115135341A (zh) 2020-01-03 2022-09-30 因赛特公司 抗cd73抗体及其用途
BR112022020256A2 (pt) * 2020-04-09 2023-01-03 Aprilbio Co Ltd “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
EP4141030A4 (en) * 2020-04-22 2024-09-04 Akeso Biopharma Inc ANTI-CD73 ANTIBODIES AND USE THEREOF
CN115867582A (zh) * 2020-05-29 2023-03-28 朝途生物疗法株式会社 抗cd73抗体及其用途
CN115734972A (zh) 2020-06-22 2023-03-03 信达生物制药(苏州)有限公司 抗cd73抗体及其用途
US20230374064A1 (en) 2020-10-05 2023-11-23 Bristol-Myers Squibb Company Methods for concentrating proteins
TW202222840A (zh) * 2020-12-11 2022-06-16 大陸商上海華奧泰生物藥業股份有限公司 Ｃｄ７３的抗原結合蛋白及其應用
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
JP2024516581A (ja) * 2021-02-24 2024-04-16 蘇州近岸蛋白質科技股▲ふん▼有限公司 抗ヒトｃｄ７３抗体およびその適用
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
CN116903744B (zh) * 2022-08-12 2024-03-08 南京蓬勃生物科技有限公司 抗cd73抗体或其抗原片段及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024116140A1 (en) 2022-12-01 2024-06-06 Medimmune Limited Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies
CN116813786A (zh) * 2023-08-03 2023-09-29 贝达药业股份有限公司 抗cd73抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182A (zh) * 2008-10-06 2011-11-09 米纳瓦生物技术公司 Muc1*抗体

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
AU2003243651B2 (en) * 2002-06-17 2008-10-16 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Specificity grafting of a murine antibody onto a human framework
US20070134249A1 (en) * 2005-12-08 2007-06-14 Genitope Corporation Combination therapy and antibody panels
NZ600758A (en) * 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8362210B2 (en) * 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
RU2603284C2 (ru) * 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
KR20140064768A (ko) 2011-07-01 2014-05-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 항-프로퍼딘 항체 및 그의 용도
TWI660972B (zh) * 2012-09-10 2019-06-01 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
WO2014130965A1 (en) * 2013-02-22 2014-08-28 Amgen Inc. Gastrokine-1 (gkn1) binding proteins and methods of treatment
WO2014153424A1 (en) * 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
ES2839087T3 (es) * 2013-11-12 2021-07-05 Ogd2 Pharma Anticuerpo derivado de IGG1 humana con actividad pro-apoptótica
EP4112070A1 (en) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EA201891366A1 (ru) * 2015-12-09 2018-12-28 Корвус Фармасьютикалз, Инк. Гуманизированные антитела против cd73

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102239182A (zh) * 2008-10-06 2011-11-09 米纳瓦生物技术公司 Muc1*抗体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Antibody humanization methods-a review and update.;Yaghoub Safdari, et al.;《Biotechnology and Genetic Engineering Reviews》;20130802;第175-186页 *
Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells.;Mikkel G.Trep, et al.;《The Journal of Immunology》;20130916;第4165-4173页 *
Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5"-nucleotidase(CD73).;L.F.Thomson, et al.;《Tissue Antigens》;19900131;摘要，第14、15页 *
Targeting Cancer-Derived Adenosine: New Therapeutic Approaches.;Arabella Young, et al.;《Cancer Discovery》;20140831;摘要，第882-886页 *

Also Published As

Publication number Publication date
IL259927A (en) 2018-07-31
EP3387442A4 (en) 2019-05-08
MX2018006973A (es) 2019-05-16
ZA201803874B (en) 2020-11-25
CN114805575A (zh) 2022-07-29
IL259927B2 (en) 2023-05-01
US20190077873A1 (en) 2019-03-14
US20210253727A1 (en) 2021-08-19
EA201891366A1 (ru) 2018-12-28
CA3007646A1 (en) 2017-06-15
CN114805575B (zh) 2024-07-23
JP7391510B2 (ja) 2023-12-05
AU2016366548B2 (en) 2023-12-14
WO2017100670A1 (en) 2017-06-15
KR20180134837A (ko) 2018-12-19
CN109154611A (zh) 2019-01-04
US11859007B2 (en) 2024-01-02
AU2016366548C1 (en) 2024-07-25
CL2018001512A1 (es) 2019-03-08
EP3387442A1 (en) 2018-10-17
JP2019503709A (ja) 2019-02-14
US10822426B2 (en) 2020-11-03
IL259927B1 (en) 2023-01-01
AU2016366548A1 (en) 2018-06-28
JP2022104941A (ja) 2022-07-12

Similar Documents

Publication Publication Date Title
CN109154611B (zh) 人源化抗cd73抗体
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
RU2756275C2 (ru) Антитела, специфические к рецептору полиовируса (pvr) человека
JP7070932B2 (ja) Ｂａｆｆ－ｒ標的化キメラ抗原受容体修飾ｔ細胞及びその使用
JP2022515318A (ja) 抗体及びその用途
MX2012011234A (es) Anticuerpos contra csf-1r.
KR20150003169A (ko) Ｄｌｌ3 조절물질들 및 사용 방법
US10533046B2 (en) Anti-CK8 antibodies for use in the treatment of colorectal cancers
CN113412124A (zh) Baff-r双特异性t细胞衔接子抗体
CN112876563B (zh) 药物组合物及其制备方法和应用
CN111518208B (zh) 抗cd47抗体及其应用
KR20180098570A (ko) 항-ｍｙｌ9 항체
CN112969715B (zh) 一种抗cd47抗原结合蛋白及其应用
EA042795B1 (ru) Гуманизированные антитела против cd73
JP2024508673A (ja) Ｃｃｄｃ１１２に基づく腫瘍細胞の増殖を抑制する方法
CN114599678A (zh) Il1rap抗体
US20190071518A1 (en) Pharmaceutical composition for the treatment of adam17 substrate dependent cancers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant